BioCryst Pharmaceuticals, Inc. (BCRX) Posts Q4 Loss of 22c/Share

February 19, 2013 6:14 AM EST Send to a Friend
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 EPS of ($0.22), $0.06 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $4.1 million versus the consensus estimate of $4.02 million.

For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings

Add Your Comment